Drug Testing Appropriateness Document Public Comment Period Open

by ASAM Staff | February 3, 2017

(North Bethesda, MD) - The American Society of Addiction Medicine (ASAM) is inviting public comment on a draft of its drug testing appropriateness document. The document will provide guidance on the use of drug testing in the diagnosis, treatment, and promotion of recovery for patients with, or at risk for, addiction. Intended for addiction specialists and all providers utilizing drug testing in the context of addiction treatment, this document strives to identify and define clinical decision-making junctures that meet the needs of most patients in most circumstances; while emphasizing that not all cases necessitate the same treatment. It touches on the principles and process of drug testing in addiction treatment, key elements of a testing program, biological matrices, settings and levels of care, special populations, and areas for further research.

ASAM’s Quality Improvement Council (QIC) appointed an expert writing panel and commissioned the Institute for Research, Education and Training in Addictions (IRETA) to lead the development of this document using a structured consensus process combining scientific evidence with clinical knowledge to yield a set of recommended actions based on a rating panel process. 

The draft document is now open for external review.  We encourage all members of ASAM, as well as other stakeholders, to participate.

Reviewers have 25 days until Tuesday, February 28, 2017 at 5:00 p.m. ET to submit their comments. All feedback will be examined by the QIC to determine if any further modifications are required before the document is submitted to the ASAM Board of Directors for approval.    

Please note that the recommendations in this manuscript are still draft and should not be copied, disseminated or implemented until final publication.  All comments can be submitted through the online tool, which also includes a conflict of interest form that must be completed in order to finalize submission. 

If you have any questions regarding the document please contact ASAM at by February 28, 2017.

More information

Media Contact:

Bob Davis 301-547-4112 or